

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



The following tables provide COVID-19 vaccination schedules based on age, health status, and product. For detailed guidance see [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#).

Table 1a. For people who are **NOT** moderately or severely immunocompromised*

2024–25 Moderna COVID-19 Vaccine			
Vaccine type: mRNA Do NOT use any previously available Moderna COVID-19 vaccine products.			
If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
6 months through 4 years†	Unvaccinated (0 doses)	Give a 2-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 4–8 weeks after Dose 1.‡ 	0.25 mL/25 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1)§	Complete the series. Give: <ul style="list-style-type: none"> • Dose 2 at least 4–8 weeks after Dose 1.‡ 	
	2 or more previous doses of any Moderna COVID-19 vaccine, NOT including at least 1 dose of 2024–25 vaccine§	Give 1 dose at least 8 weeks after the last dose.	
	2 or more previous doses of any Moderna COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 vaccine§	No further doses are indicated.	
5 through 11 years¶	Unvaccinated (0 doses)	Give 1 dose now.	0.25 mL/25 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2024–25 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 vaccine	No further doses are indicated.	
12 years and older	Unvaccinated (0 doses)	Give 1 dose now.	0.5 mL/50 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2024–25 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 vaccine**	No further doses are indicated.	

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Children 6 months through 4 years of age should receive the same vaccine product for all doses. In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ An 8-week interval between the first and second doses of Moderna COVID-19 Vaccine might be optimal for some people, as it might reduce the rare risk of myocarditis and pericarditis associated with COVID-19 vaccines.

§ If mRNA vaccine is administered from different manufacturers, a 3-dose initial series should be followed:

- Children who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4–8 weeks after Dose 1.
 - Dose 3 at least 8 weeks after Dose 2.
- Children who received 2 doses of vaccine from different manufacturers, administer Dose 3 at least 8 weeks after Dose 2.

¶ CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn 5 years of age during the initial series, administer 1 dose at least 4–8 weeks after Dose 1. There is no dosage change. No further doses are indicated.

** If the immunization history is only 1 dose of 2024–25 Novavax COVID-19 vaccine, see Table 1c for detailed guidance.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 1b. For people who are **NOT** moderately or severely immunocompromised*

2024–25 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
6 months through 4 years[†]	Unvaccinated (0 doses)	Give a 3-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3–8 weeks after Dose 1.[‡] • Dose 3 at least 8 weeks after Dose 2. 	0.3 mL/3 µg from a yellow-capped multidose vial Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [§]	Complete the before series. Give: <ul style="list-style-type: none"> • Dose 2 at least 3–8 weeks after Dose 1.[‡] • Dose 3 at least 8 weeks after Dose 2. 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [§]	Complete the series. Give: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks after Dose 2. 	
	3 or more previous doses of any Pfizer-BioNTech COVID-19 vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine [§]	Give 1 dose at least 8 weeks after the last dose.	
	3 or more previous doses of any Pfizer-BioNTech COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	No further doses are indicated.	
5 through 11 years[¶]	Unvaccinated (0 doses)	Give 1 dose now.	0.3 mL/10 µg from a blue-capped single dose vial Intramuscular (IM) injection
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	No further doses are indicated.	
12 years and older	Unvaccinated (0 doses)	Give 1 dose now.	0.3 mL/30 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine ^{**}	No further doses are indicated.	

* People with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Children 6 months through 4 years of age should receive the same vaccine product for all doses. In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ An 8-week interval between the first and second doses of Pfizer-BioNTech COVID-19 Vaccine might be optimal for some people, as it might reduce the rare risk of myocarditis and pericarditis associated with COVID-19 vaccines.

§ If mRNA vaccine is administered from different manufacturers, a 3-dose initial series should be followed:

- Children who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4–8 weeks after Dose 1.
 - Dose 3 at least 8 weeks after Dose 2.
- Children who received 2 doses of vaccine from different manufacturers, administer Dose 3 at least 8 weeks after Dose 2.

¶ CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn 5 years of age during the initial series, administer the age-appropriate dose 0.3 mL/10 µg. If the 10 µg dose is the second dose, administer at least 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose. No further doses are indicated.

** If the immunization history is only 1 dose of 2024–25 Novavax COVID-19 vaccine, see Table 1c for detailed guidance.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 1c. For people who are **NOT** moderately or severely immunocompromised*

2024–25 Novavax COVID-19 Vaccine Vaccine type: Protein subunit Do NOT use any previously available Novavax COVID-19 vaccine products.			
If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
12 years and older	Unvaccinated (0 doses)	Give a 2-dose initial series. • Dose 1 now • Dose 2 at least 3–8 weeks after Dose 1 [†]	0.5 mL/5 µg rS protein and 50 µg Matrix-M adjuvant in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	1 previous dose of 2024–25 Novavax COVID-19 Vaccine (Dose 1)	Give Dose 2 at least 3–8 weeks after the last dose. [†]	
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2024–25 vaccine	Give 1 dose at least 8 weeks after the last dose	
	Any number of previous doses of COVID-19 vaccine, WITH at least 1 dose of 2024–25 vaccine [‡]	No further doses are indicated.	

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† An 8-week interval between the first and second doses of Novavax COVID-19 vaccine might be optimal for some people, as it might reduce the rare risk of myocarditis and pericarditis associated with COVID-19 vaccines.

‡ If the immunization history is only 1 dose of 2024–25 Novavax COVID-19 vaccine (Dose 1), administer 1 dose of 2024–25 Novavax vaccine at least 3–8 weeks after Dose 1.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised

2024–25 Moderna COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Moderna COVID-19 vaccine products.

If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
6 months through 11 years*	Unvaccinated (0 doses)	Give a 3-dose initial series. [†] <ul style="list-style-type: none"> Dose 1 now. Dose 2 at least 4 weeks after Dose 1. Dose 3 at least 4 weeks after Dose 2. 	0.25 mL/25 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [‡]	Complete the series. [†] Give: <ul style="list-style-type: none"> Dose 2 at least 4 weeks after Dose 1. Dose 3 at least 4 weeks after Dose 2. 	
	2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [‡]	Complete the series. [†] Give: <ul style="list-style-type: none"> Dose 3 at least 4 weeks after Dose 2. 	
	3 or more previous doses of Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine [‡]	Give 1 dose at least 8 weeks after the last dose.	
	3 or more previous doses of Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	<ul style="list-style-type: none"> These children may receive 1 additional dose at least 8 weeks following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks after the last COVID-19 vaccine dose. 	

* Children 6 months through 4 years of age should receive the same vaccine products for all doses.

† In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ If mRNA vaccine is administered from different manufacturers, complete the recommended 3-dose series.

- For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4 weeks after Dose 1.
 - Dose 3 at least:
 - 8 weeks after Dose 2 for children 6 months through 4 years of age.
 - 4 weeks after Dose 2 for people 5 years of age and older.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised *Continued*

2024–25 Moderna COVID-19 Vaccine - CONTINUED			
Vaccine type: mRNA Do NOT use any previously available Moderna COVID-19 vaccine products.			
If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
5 through 11 years of age*	Unvaccinated (0 doses)	Give a 3-dose initial series. [†] <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. 	0.25 mL/25 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [‡]	Complete the series. [†] Give: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. 	
	2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [‡]	Complete the series. [†] Give: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. 	
	3 or more doses Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2024–25 vaccine [‡]	Give 1 dose at least 8 weeks after the last dose.	
	3 or more doses Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 vaccine	1 additional dose may be administered at least 8 weeks following the last dose. Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. Administer additional doses at least 8 weeks after the last dose.	

* People 5 years of age and older should receive the same vaccine product for the recommended 3-dose series. Additional doses may be any age-appropriate product.

† In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ If mRNA vaccine is administered from different manufacturers, complete the recommended 3-dose series.

- For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4 weeks after Dose 1.
 - Dose 3 at least:
 - 8 weeks after Dose 2 for children 6 months through 4 years of age.
 - 4 weeks after Dose 2 for people 5 years of age and older.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised *Continued*

2024-25 Moderna COVID-19 Vaccine - CONTINUED

Vaccine type: mRNA | Do NOT use any previously available Moderna COVID-19 vaccine products.

If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
12 years and older**	Unvaccinated 0 doses	Give a 3-dose initial series. [‡] <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. 	0.5 mL/50 µg in a manufacturer-filled syringe (MFS) Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [§]	Complete the series. [‡] Give: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. 	
	2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [§]	Complete the series. [‡] Give: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. 	
	3 or more previous doses of any mRNA COVID-19 Vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	3 or more previous doses of any mRNA COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	1 additional dose may be administered at least 8 weeks following the last dose. Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. Administer additional doses at least 8 weeks after the last dose.	
	2 or more doses of Novavax, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the previous dose.	
	2 or more doses of Novavax, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	<ul style="list-style-type: none"> • People who are moderately or severely immunocompromised may receive 1 additional dose at least 8 weeks following the last recommended dose. • Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks after the last COVID-19 vaccine dose 	

* People 5 years of age and older should receive the same vaccine product for the recommended 3-dose series. Additional doses may be any age-appropriate product.

† CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn 12 years of age during the 3-dose series should complete the series with age-appropriate dose **0.5 mL/50µg**.

‡ In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

§ If mRNA vaccine is administered from different manufacturers, complete the recommended 3-dose series.

For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:

- Dose 2 at least 4 weeks after Dose 1.
- Dose 3 at least:
 - 8 weeks after Dose 2 for children 6 months through 4 years of age.
 - 4 weeks after Dose 2 for people 5 years of age and older.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised

2024–25 Pfizer-BioNTech COVID-19 Vaccine Vaccine type: mRNA Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.			
If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
6 months through 4 years*	Unvaccinated (0 doses)	Give a 3-dose initial series. [†] <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks after Dose 2. 	0.3 mL/3 µg from a yellow-capped multidose vial Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [‡]	Complete the series. [†] Give: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks after Dose 2. 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [‡]	Complete series. [†] Give: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks after Dose 2. 	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine [‡]	Give 1 dose at least 8 weeks after the last dose.	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	<ul style="list-style-type: none"> • These children may receive 1 additional dose at least 8 weeks following the last recommended dose.[‡] • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances.[‡] • Any further additional doses should be administered at least 8 weeks after the last COVID-19 vaccine dose.[‡] 	

* Children 6 months through 4 years of age should receive the same vaccine products for all doses.

† If mRNA vaccine is administered from different manufacturers, complete the recommended 3-dose series.

• For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:

◦ Dose 2 at least 4 weeks after Dose 1.

◦ Dose 3 at least:

◦ 8 weeks after Dose 2 for children 6 months through 4 years of age.

◦ 4 weeks after Dose 2 for people 5 years of age and older.

‡ In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised *Continued*

2024–25 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA | Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
5 through 11 years ^{*,†}	Unvaccinated (0 doses)	Give a 3-dose initial series. [‡] <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. 	0.3 mL/10 µg from a blue-capped single-dose vial Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [§]	Complete the series. [‡] Give: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [§]	Complete the series. [‡] Give: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2. 	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the last dose	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	<ul style="list-style-type: none"> • These children may receive 1 additional dose at least 8 weeks following the last recommended dose. • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks after the last COVID-19 vaccine dose. 	

* People 5 years of age and older should receive the same vaccine product to complete a 3-dose series. Additional doses may be any age-appropriate product.

† CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn:

- 5 years of age during the 3-dose series should complete the series with age-appropriate dose **0.3 mL/10 µg**.
- 12 years of age during the 3-dose series should complete the series with age-appropriate dose **0.5 mL/50 µg**.

‡ In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

§ If mRNA vaccine is administered from different manufacturers, complete the recommended 3-dose series.

- For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4 weeks after Dose 1.
 - Dose 3 at least:
 - 8 weeks after Dose 2 for children 6 months through 4 years of age.
 - 4 weeks after Dose 2 for people 5 years of age and older.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised *Continued*

2024–25 Pfizer-BioNTech COVID-19 Vaccine - CONTINUED

Vaccine type: mRNA | Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
12 years and older**†	Unvaccinated 0 doses	Give a 3-dose initial series.‡ • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2.	0.3 mL/30 µg from a manufacturer-filled syringe Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1)§	Complete the series.‡ Give: • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2.	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2)§	Complete the series.‡ Give: • Dose 3 at least 4 weeks after Dose 2.	
	3 or more previous doses of any mRNA COVID-19 Vaccine, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	3 or more previous doses of any mRNA COVID-19 Vaccine, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	1 additional dose may be administered at least 8 weeks following the last dose. Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. Administer additional doses at least 8 weeks after the last dose.	
	2 or more doses of Novavax, NOT including at least 1 dose of 2024–25 COVID-19 vaccine	Give 1 dose at least 8 weeks after the previous dose.	
	2 or more doses of Novavax, INCLUDING at least 1 dose of 2024–25 COVID-19 vaccine	• People who are moderately or severely immunocompromised may receive 1 additional dose at least 8 weeks following the last recommended dose. • Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks after the last COVID-19 vaccine dose	

* People 5 years of age and older should receive the same vaccine product to complete a 3-dose series. Additional doses may be any age-appropriate product.

† CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination. Children who turn:

- 5 years of age during the 3-dose series should complete the series with age-appropriate dose **0.3 mL/10 µg**.
- 12 years of age during the 3-dose series should complete the series with age-appropriate dose **0.5 mL/50 µg**.

‡ In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

§ If mRNA vaccine is administered from different manufacturers, complete the recommended 3-dose series.

- For people who received Dose 1 from one manufacturer but will receive subsequent dose(s) from a different manufacturer, administer:
 - Dose 2 at least 4 weeks after Dose 1.
 - Dose 3 at least:
 - 8 weeks after Dose 2 for children 6 months through 4 years of age.
 - 4 weeks after Dose 2 for people 5 years of age and older.

2024–2025 COVID-19 Vaccine Immunization Schedule

for People 6 Months of Age and Older



Table 2c. For people who **ARE** moderately or severely immunocompromised

2024–25 Novavax COVID-19 Vaccine

Vaccine type: Protein subunit | Do NOT use any previously available Novavax COVID-19 vaccine products.

If current age is:	And the COVID-19 vaccination history is:	Then:	Administer:
12 years and older*	Unvaccinated (0 doses)	Give a 2-dose initial series. <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. 	0.5 mL/5 µg rS protein and 50 µg Matrix-M adjuvant in a manufacturer-filled syringe (MFS) Intramuscular (IM) injectionw
	1 previous dose of 2024–25 Novavax COVID-19 Vaccine (Dose 1) [†]	Give Dose 2 at least 3 weeks after the last dose.	
	1 or more previous doses of any COVID-19 vaccine, NOT including at least 1 dose of 2024–25 vaccine	Give 1 dose at least 8 weeks after the last dose.	
	2 or more previous doses of any COVID-19 vaccine, INCLUDING at least 1 dose of 2024–25 vaccine	1 additional dose may be administered at least 8 weeks following the last dose. Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. Administer additional doses at least 8 weeks after the last dose.	

* Previously unvaccinated people should receive a 2-dose Novavax COVID-19 series. Additional doses may be any age-appropriate product.

† In the following situations, a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available at the time of the clinic visit, the previous dose is unknown, the person would otherwise not receive a recommended dose, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.